CD4 and Miyoshi myopathy: As shown in Figure 3, from a functional point of view, Tregs demonstrated to be able to inhibit autologous CD4+CD25− cells at a mean rate of 71.6%  ± 3% in healthy controls, 68.3%  ± 6% in MGUS, 73.3%  ± 9.1% in SMM, and 72.5%  ± 9.9% in active MM (p ns).